CDX-1135
- Generic Name
- CDX-1135
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 2RF4H67MOG
- Background
CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT01791686
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath